Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Can...
May 30 2019 - 4:30PM
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced that Ray Mannion, Zynerba’s Vice President of
Manufacturing, will provide a formal presentation during the U.S.
Food and Drug Administration’s (FDA) Public Hearing on Scientific
Data and Information about Products Containing Cannabis or
Cannabis-Derived Compounds. As noted in the Federal Register, the
public hearing is scheduled from 8:00 a.m. to 6:00 p.m. ET
tomorrow, May 31, 2019.
Slides from Mr. Mannion’s presentation, entitled
‘Cannabinoid Manufacturing and Product Quality’, are now available
on Zynerba’s corporate website at
https://zynerba.com/publications/.
“The FDA has a well-established history of
protecting public health and safety through a variety of essential
strategies, including existing regulations and processes that
govern the manufacture of pharmaceutical products and establish
controls to ensure necessary quality and safety standards are met,”
said Armando Anido, Chairman and Chief Executive Officer of
Zynerba. “This existing robust framework should be leveraged in the
regulation of all cannabinoid products, as less stringent
manufacturing and quality standards would create an unnecessary
public health risk.”
Ray Mannion has served as Zynerba’s Vice President
of Manufacturing since April 2017. He has more than 35 years of
international manufacturing, operations and engineering experience
in the pharmaceutical, medical devices and electrical connection
systems industries. Prior to Zynerba, he was Senior Director, Third
Party Operations for Teva Pharmaceuticals Inc. where he
successfully managed the production scale up for the commercial
launch of the Zecuity® migraine patch while also managing all
technical aspects of the project. Prior to Teva, Mr. Mannion
held roles of increasing responsibility at NuPathe, Puricore,
Kensey Nash Corporation, AMP Incorporated and others. Mr. Mannion
received a B.S. in Industrial Engineering from Rutgers University
and an M.B.A from Shippensburg University.
About Zynerba Pharmaceuticals,
Inc. Zynerba Pharmaceuticals is the leader in
pharmaceutically-produced transdermal cannabinoid therapies for
rare and near-rare neuropsychiatric disorders. We are committed to
improving the lives of patients and their families living with
severe, chronic health conditions including Fragile X Syndrome,
Autism Spectrum Disorder, 22q11.2 Deletion Syndrome, and a
heterogeneous group of rare and ultra-rare epilepsies known as
developmental and epileptic encephalopathies. Learn more at
www.zynerba.com and follow us on Twitter at
@ZynerbaPharma.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the Company’s current
expectations. These and other risks are described in the
Company’s periodic reports, including the annual report on Form
10-K, quarterly reports on Form 10-Q and current reports on Form
8-K, filed with or furnished to the Securities and Exchange
Commission and available at www.sec.gov. Any forward-looking
statements that the Company makes in this press release speak only
as of the date of this press release. The Company assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise, after the date of
this press release.
Investor ContactWilliam Roberts, Vice
President, Investor Relations and Corporate CommunicationsZynerba
Pharmaceuticals484.581.7489 robertsw@zynerba.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024